3 Contract Development Company, Pain and Chronic Care Brand Owner and Active Ingredients Maker Stocks With a Strong Future Roadmap: Anthem Biosciences, Ipca Laboratories and Granules India

Anthem Biosciences, Ipca Laboratories and Granules India: ROE of 11.7% to 19.4% and FY22 to FY26 revenue CAGR of 9.2% to 15.5%. Prices as of 27 Oct 2026.

Updated: 28 Oct 2026 • 1:12 pm

Posted by:

Quick Answer

The three development, pain brand and API pharma to watch are Anthem Biosciences, Ipca Laboratories and Granules India. Their return on equity ranges from 11.7% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 15.5%. Anthem Biosciences leads on both return on equity at 19.4% and revenue growth at 15.5% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.

Development, pain brand and API pharma bring together companies with a visible plan for the years ahead. Anthem Biosciences, Ipca Laboratories and Granules India cover a contract development company, a pain and chronic care brand owner and an active ingredients maker.

This list covers three development, pain brand and API pharma with complete current figures: Anthem Biosciences, Ipca Laboratories and Granules India. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

What Are Development, Pain Brand and API Pharma?

Development, pain brand and API pharma are listed pharmaceutical companies that develop and manufacture drugs for global customers, sell leading brands in pain management and other therapies and make active ingredients and finished dosages. Their earnings depend on contracts, approvals and export demand.

Development, Pain Brand and API Pharma at a Glance

Company	CMP (Rs)	Market Cap (Rs Cr)	P/E	Industry P/E	ROE (%)	D/E
Anthem Biosciences	837.15	45,546	79.1	36.0	19.4	0.02
Ipca Laboratories	1,980.8	46,050	33.5	36.0	14.2	0.10
Granules India	830.55	22,002	33.2	36.0	11.7	0.30

On valuation, Ipca Laboratories and Granules India trade at a P/E below the industry P/E, while Anthem Biosciences trades above it, which reflects the growth the market already expects. Readers comparing development, pain brand and API pharma should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Development, Pain Brand and API Pharma Have a Strong Roadmap in India?

Development, pain brand and API pharma have a strong roadmap in India because outsourcing of drug development and manufacturing, steady domestic brand demand and global supply chain diversification keep widening the market for Indian pharmaceutical firms.

Contract work. Global firms outsource development and output.
Domestic brands. Pain and chronic care see steady use.
Ingredient supply. Customers diversify sourcing to India.

Why Anthem Biosciences Features Among These Development, Pain Brand and API Pharma

Among the development, pain brand and API pharma on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.

Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.

Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.

Why Ipca Laboratories Features Among These Development, Pain Brand and API Pharma

Among the CDMO, branded generics and ingredient shares on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.

The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.

Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore.

Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.

Why Granules India Features Among These Development, Pain Brand and API Pharma

Among the three companies on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.

Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%.

In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.

Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What to watch: Monitor new product approvals and the share of finished dosages in total sales.

Anthem Biosciences vs Ipca Laboratories vs Granules India on Key Financials

The table below sets the three development, pain brand and API pharma side by side on revenue, profit and margin, using reported figures.

Company	FY22 Revenue (Rs Cr)	FY26 Revenue (Rs Cr)	Revenue CAGR (FY22-FY26)	FY26 Net Profit (Rs Cr)	FY26 Net Margin
Anthem Biosciences	1,280	2,280	15.5%	592	26.0%
Ipca Laboratories	5,896	9,821	13.6%	1,191	12.1%
Granules India	3,783	5,386	9.2%	595	11.0%

Anthem Biosciences posts the highest return on equity in this group at 19.4%. Ipca Laboratories has the largest FY26 revenue at Rs 9,821 crore, and Anthem Biosciences shows the fastest revenue growth with a 15.5% compound annual rate. A useful habit with development, pain brand and API pharma is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Development, Pain Brand and API Pharma

Every theme carries risks that deserve a check before any decision. For these development, pain brand and API pharma, the main points are: Long-term CDMO, branded generics and ingredient shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

Regulatory approvals. Plant inspections and approvals can affect supplies.
Currency moves. Export earnings move with the rupee.
Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter development, pain brand and API pharma by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Development, Pain Brand and API Pharma

Development, pain brand and API pharma suit investors who prefer to study business strength before price moves. Anthem Biosciences, Ipca Laboratories and Granules India each have a clear plan to grow. Based on the 27 October 2026 close, Anthem Biosciences trades at Rs 837.15, Ipca Laboratories at Rs 1,980.8 and Granules India at Rs 830.55. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these development, pain brand and API pharma to a watchlist.

Download the Univest iOS App or Univest Android App to track development, pain brand and API pharma, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are development, pain brand and API pharma?

Ans. Development, pain brand and API pharma are listed pharmaceutical companies that develop and manufacture drugs for global customers, sell leading brands in pain management and other therapies and make active ingredients and finished dosages. Their earnings depend on contracts, approvals and export demand. This list looks at three of them, Anthem Biosciences, Ipca Laboratories and Granules India, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.

Which development, pain brand and API pharma are covered in this list?

Ans. This list covers Anthem Biosciences, Ipca Laboratories and Granules India. Based on the 27 October 2026 close, Anthem Biosciences traded at Rs 837.15, Ipca Laboratories at Rs 1,980.8 and Granules India at Rs 830.55. Their return on equity ranges from 11.7% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.2% to 15.5%.

Why do development, pain brand and API pharma have a strong future roadmap in India?

Ans. Development, pain brand and API pharma have a strong roadmap in India because outsourcing of drug development and manufacturing, steady domestic brand demand and global supply chain diversification keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Contract work. Global firms outsource development and output. Domestic brands. Pain and chronic care see steady use. Ingredient supply. Customers diversify sourcing to India. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Anthem Biosciences performed financially?

Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

How has Ipca Laboratories performed financially?

Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

How has Granules India performed financially?

Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What risks should investors check before buying development, pain brand and API pharma?

Ans. Investors should check a few risks before buying development, pain brand and API pharma. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of development, pain brand and API pharma investment advice?

Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.